Mithra Pharmaceuticals SA Probability of Future Pink Sheet Price Finishing Over 6.75
| MITPFDelisted Stock | USD 6.75 0.00 0.00% |
Mithra |
Mithra Pharmaceuticals Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Mithra Pharmaceuticals for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Mithra Pharmaceuticals can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Mithra Pharmaceuticals is not yet fully synchronised with the market data | |
| Mithra Pharmaceuticals has a very high chance of going through financial distress in the upcoming years | |
| Mithra Pharmaceuticals SA has accumulated 125.24 M in total debt with debt to equity ratio (D/E) of 9.62, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Mithra Pharmaceuticals has a current ratio of 0.78, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist Mithra Pharmaceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, Mithra Pharmaceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Mithra Pharmaceuticals sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Mithra to invest in growth at high rates of return. When we think about Mithra Pharmaceuticals' use of debt, we should always consider it together with cash and equity. | |
| The entity reported the revenue of 22.67 M. Net Loss for the year was (116.88 M) with profit before overhead, payroll, taxes, and interest of 6.94 M. | |
| Mithra Pharmaceuticals SA has accumulated about 29.3 M in cash with (74.39 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.59. | |
| Roughly 32.0% of Mithra Pharmaceuticals outstanding shares are owned by corporate insiders |
Mithra Pharmaceuticals Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Mithra Pink Sheet often depends not only on the future outlook of the current and potential Mithra Pharmaceuticals' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Mithra Pharmaceuticals' indicators that are reflective of the short sentiment are summarized in the table below.
Mithra Pharmaceuticals Technical Analysis
Mithra Pharmaceuticals' future price can be derived by breaking down and analyzing its technical indicators over time. Mithra Pink Sheet technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Mithra Pharmaceuticals SA. In general, you should focus on analyzing Mithra Pink Sheet price patterns and their correlations with different microeconomic environments and drivers.
Mithra Pharmaceuticals Predictive Forecast Models
Mithra Pharmaceuticals' time-series forecasting models is one of many Mithra Pharmaceuticals' pink sheet analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Mithra Pharmaceuticals' historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the pink sheet market movement and maximize returns from investment trading.
Things to note about Mithra Pharmaceuticals
Checking the ongoing alerts about Mithra Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Mithra Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| Mithra Pharmaceuticals is not yet fully synchronised with the market data | |
| Mithra Pharmaceuticals has a very high chance of going through financial distress in the upcoming years | |
| Mithra Pharmaceuticals SA has accumulated 125.24 M in total debt with debt to equity ratio (D/E) of 9.62, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Mithra Pharmaceuticals has a current ratio of 0.78, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist Mithra Pharmaceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, Mithra Pharmaceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Mithra Pharmaceuticals sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Mithra to invest in growth at high rates of return. When we think about Mithra Pharmaceuticals' use of debt, we should always consider it together with cash and equity. | |
| The entity reported the revenue of 22.67 M. Net Loss for the year was (116.88 M) with profit before overhead, payroll, taxes, and interest of 6.94 M. | |
| Mithra Pharmaceuticals SA has accumulated about 29.3 M in cash with (74.39 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.59. | |
| Roughly 32.0% of Mithra Pharmaceuticals outstanding shares are owned by corporate insiders |
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in inflation. You can also try the Headlines Timeline module to stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity.
Other Consideration for investing in Mithra Pink Sheet
If you are still planning to invest in Mithra Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Mithra Pharmaceuticals' history and understand the potential risks before investing.
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes |